Damora Therapeutics (DMRA) PT Lowered to $55 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Andrew Berens lowered the price target on Damora Therapeutics (NASDAQ: DMRA) to $55.00 (from $57.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
